指南与共识免疫规划卫生政策与健康促进

美国27-45岁成年人人乳头瘤病毒疫苗接种覆盖率:共享临床决策推荐后3年

Human Papillomavirus Vaccination Coverage Among Adults Aged 27-45 Years in the U.S., 3 Years After the Recommendation for Shared Clinical Decision Making.
指南 / 共识 · Am J Prev Med · 2025-11-04

基于2022年美国国家健康访谈调查和2021-2023年美国国家健康与营养检查调查,评估27-45岁成年人人乳头瘤病毒疫苗接种情况,并与2019年及2017-2018年数据比较。结果显示2022年接种覆盖率21.8%,较2019年提高6.3个百分点;2021-2023年覆盖率为26.6%,较2017-2018年提高16.7个百分点;但在27岁前未接种者中覆盖率仅2.7%,较2019年提高0.9个百分点。结论认为尽管覆盖率有所增加,该年龄段接种率仍较低,且在该年龄段接种者很少。

要点

  • 2022年27-45岁成年人HPV疫苗接种覆盖率为21.8%,较2019年提高6.3个百分点。
  • 2021-2023年该人群接种覆盖率为26.6%,较2017-2018年提高16.7个百分点。
  • 27岁前未接种者中覆盖率仅2.7%,较2019年提高0.9个百分点。

核心结论

  • 2022年27-45岁成年人HPV疫苗接种率较低,尽管较2019年有所增加。
  • 在该年龄段接种的成年人很少,随着常规推荐和补种年龄组接种者进入该人群,覆盖率可能增加。
  • 进一步调查可了解该年龄段的总体覆盖率及不同亚群中共享临床决策的使用情况。

研究设计与样本

  • 基于2022年美国国家健康访谈调查评估27-45岁成年人HPV疫苗接种(≥1剂),并与2019年结果比较。
  • 基于2021-2023年美国国家健康与营养检查调查评估接种情况,并与2017-2018年结果比较。
  • 分析于2025年进行。

主要发现

  • 2022年27-45岁成年人HPV疫苗接种覆盖率为21.8%,较2019年提高6.3个百分点(基于国家健康访谈调查)。
  • 2021-2023年覆盖率为26.6%,较2017-2018年提高16.7个百分点(基于国家健康与营养检查调查)。
  • 27岁前未接种者中,基于国家健康访谈调查的覆盖率为2.7%,较2019年提高0.9个百分点。
  • 在27岁前未接种者中,与较高HPV疫苗接种独立相关的因素包括年龄较大、女性、未婚以及有固定医生提供医疗服务。

关键数值与推荐

  • 2019年,免疫实践咨询委员会推荐采用共享临床决策考虑对27-45岁成年人进行HPV疫苗接种。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2019, shared clinical decision making was recommended by the Advisory Committee on Immunization Practices for consideration of human papillomavirus vaccination of adults aged 27-45 years. This study aims to assess human papillomavirus vaccination among adults aged 27-45 years 3 years after shared clinical decision making recommendation. METHODS: Human papillomavirus vaccination (≥1 dose) among adults aged 27-45 years was assessed from the 2022 National Health Interview Survey and compared with results from 2019; vaccination from the 2021-2023 National Health and Nutrition Examination Survey was assessed and compared with results from 2017-2018. Analyses were conducted in 2025. RESULTS: Human papillomavirus vaccination coverage among adults aged 27-45 years was 21.8% in 2022, 6.3 percentage points higher than 2019 based on the National Health Interview Survey; coverage was 26.6% in 2021-2023, 16.7 percentage points higher than 2017-2018 based on the National Health and Nutrition Examination Survey. Among adults aged 27-45 years who were not vaccinated before age 27 years, coverage based on the National Health Interview Survey was 2.7%, an increase of 0.9 percentage points compared with 2019. Factors independently associated with higher human papillomavirus vaccination among those not vaccinated before age 27 years included older age, female sex, not being married, and having a regular physician for health care. CONCLUSIONS: Human papillomavirus vaccination among adults aged 27-45 years in 2022 was low despite an increase in coverage from 2019. Few adults were vaccinated at age 27-45 years. As persons vaccinated in routinely recommended and catch-up age groups progress into this population, coverage is likely to increase. Further surveys in this age group can inform overall coverage as well as use of shared clinical decision making in different population subgroups.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Lu PJ, Hung MC, Lewis RM, et al. Human Papillomavirus Vaccination Coverage Among Adults Aged 27-45 Years in the U.S., 3 Years After the Recommendation for Shared Clinical Decision Making. Am J Prev Med. 2025. PMID: 41197975. doi:10.1016/j.amepre.2025.108180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。